View Filing Data

Summary of Significant Accounting Policies

(3)

Summary of Significant Accounting Policies

Use of Estimates

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

Cash Equivalents and Concentrations of Credit Risk

The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

Restricted Cash

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified.

Inventories

Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory.

Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2017 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. The Company evaluates property, plant and equipment for impairment periodically to determine if changes in circumstances or the occurrence of events suggest the carrying value of the asset or asset group may not be recoverable. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with Accounting Standards Codification (ASC) 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges.

Fair Value Measurements

The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

•

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

•

Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

•

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Revenue Recognition

Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.

Deferred Revenue

Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.

Selling, General and Administrative

Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.

Research and Development

Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.

Stock Based Compensation

The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Underthe provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expenses its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

Income Taxes

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information.

Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows:


(in thousands, except share data)	2017			2016			2015
Net loss	$	(45,117	)	$	(17,971	)	$	(14,704	)
Preferred stock dividends		(527	)		—			—

Net loss, adjusted		(45,644	)		(17,971	)		(14,704	)
Net loss per share – basic and diluted		(3,250	)		(1,853,500	)		(2,548,000	)
Weighted average shares outstanding – basic and diluted		14,039			10			6

In the third quarter of 2017, the Company issued Series B Preferred Shares. A portion of the redemption price of the Series B Preferred Shares was accounted for as a deemed dividend and is discussed further in Note 10.

For the years ended December 31, 2017, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:


	2017		2016		2015
Stock options		—		—		—
Unvested restricted shares		—		—		—
Warrants		14,049		41		65

Total		14,049		41		63

Segment Information

The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statements of operations.

The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.

Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company will adopt this standard on January 1, 2018 using the modified retrospective method. The Company has completed an analysis of its existing product sales and distribution agreement and assessed the differences in accounting for each under ASU 2014-09 compared with current revenue accounting standards. Based on that review, the Company does not expect the implementation of ASU 2014-09 to have a material quantitative impact on its consolidated financial statements as the timing of revenue recognition for product sales is not expected to change considerably.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company has adopted this guidance.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company will adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815). The new guidance intends to reduce the complexity associated with the issuer’s accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the Board determined that a down round feature would no longer cause a freestanding equity-linked financial instrument (or an embedded conversion option) to be accounted for as a derivative liability at fair value with changes in fair value recognized in current earnings. In addition, the Board re-characterized the indefinite deferral of certain provisions of Topic 480 to a scope exception. The re-characterization has no accounting effect. ASU 2017-11 is effective for public entities for fiscal years beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s consolidated financial statements.

Inventories

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventories

(2)

Inventories

Inventories consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Raw materials	$	275	$	298
Work-in-process		682		721
Finished goods		323		229

Total inventories	$	1,280	$	1,248

(4)

Inventories

Inventories consist of:


(in thousands)	December 31, 2017		December 31, 2016
Raw materials	$	298	$	346
Work-in-process		721		214
Finished goods		229		100

Total Inventory	$	1,248	$	660

Prepaid Expenses And Other Current Assets

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

(3)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Insurance premiums	$	337	$	421
Financing costs		—		70
VAT/GST receivable		34		29
Security Deposit		49		50
Other¹		134		130

Total prepaid expenses and other current assets	$	554	$	700

¹	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at March 31, 2018 and December 31, 2017.

(5)

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets include the following:


(in thousands)	December 31, 2017		December 31, 2016
Insurance premiums	$	421	$	501
Financing costs		70		—
Security deposit		50		50
Other¹		159		147

Total prepaid expenses and other current assets	$	700	$	698

¹	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2017 and 2016.

Property, Plant, and Equipment

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant, and Equipment

(4)

Property, Plant, and Equipment

Property, plant, and equipment consist of the following:


(in thousands)	March 31, 2018			December 31, 2017
Buildings and land	$	579		$	579
Enterprise hardware and software		1,746			1,744
Leaseholds		1,719			1,705
Equipment		971			971
Furniture		176			175

Property, plant and equipment, gross		5,191			5,174
Accumulated depreciation		(4,003	)		(3,876	)

Property, plant and equipment, net	$	1,188		$	1,298

Depreciation expense for the three months ended March 31, 2018 was approximately $0.1 million, as compared to approximately $0.1 million for the same period in 2017.

(6)

Property, Plant, and Equipment

Property, plant, and equipment consists of:


(in thousands)	December 31, 2017			December 31, 2016
Buildings and land	$	579		$	556
Enterprise hardware and software		1,744			1,532
Leaseholds		1,705			1,504
Equipment		971			940
Furniture		175			354

Property, plant and equipment, gross		5,174			4,886
Accumulated depreciation		(3,876	)		(3,803	)

Property, plant and equipment, net	$	1,298		$	1,083

Depreciation expense for the years ended December 31, 2017, 2016 and 2015 was $0.3 million, $0.3 million, $0.6 million, respectively.

Accrued Expenses

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

(5)

Accrued Expenses

Accrued expenses consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Compensation, excluding taxes	$	738	$	1,124
Clinical trial expenses		1,603		869
Professional fees		95		221
Short-term portion of lease restructuring		197		209
Other¹		893		985

Total accrued expenses	$	3,526	$	3,408

¹	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2018 and December 31, 2017.

(7)

Current Accrued Expenses

Current accrued expenses include the following:


(in thousands)	December 31, 2017		December 31, 2016
Clinical trial expenses	$	869	$	1,365
Compensation, excluding taxes		1,124		933
Professional fees		221		286
Short-term portion of lease restructuring		209		216
Other¹		985		607

Total accrued expenses	$	3,408	$	3,407

¹	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2017 and 2016.

Restructuring Expenses

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring Expenses

(6)

Restructuring Expenses

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of March 31, 2018, the total remaining lease restructuring liability for its leased office space was approximately $0.5 million, of which approximately $0.2 million and $0.3 million were included in Accrued expenses and Other non-current liabilities on the condensed consolidated balance sheets, respectively.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of March 31, 2018:


(in thousands)	Lease Liability
Reserve balance at December 31, 2017	$	604
Charges		—
Payments/Utilizations		(58	)

Reserve balance at March 31, 2018	$	546

(8)

Restructuring Expenses

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of December 31, 2017, the total remaining lease restructuring liability for its leased office space was approximately $0.6 million, of which approximately $0.2 million and $0.4 million were included in Accrued expenses and Other non-current liabilities on the consolidated balance sheets, respectively.

The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2017:


(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(216	)

Reserve balance at December 31, 2017	$	604

Convertible Notes Payable

12 Months Ended

Dec. 31, 2017

Debt Disclosure Abstract

Convertible Notes Payable

(9)

Convertible Notes Payable

As of December 31, 2017, the senior secured convertible notes (the “Notes”) had been repaid in full and were no longer outstanding.

On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of Notes and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes were secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future.

Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. The balance was released throughout 2017.

In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire approximately 40 shares of Common Stock. The provisions in the Series C Warrants required the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. On April 2, 2017 the Company entered into separate warrant repurchase agreements (the “Warrant Repurchase Agreements”) with each of the investors named on the Schedule of Buyers attached to the SPA. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case were paid to the respective investor, in exchange for cancellation of the Warrants issued to each investor under the SPA. As a result of the extinguishment, the Company recognized a gain of $9.6 million, representing the difference between the fair value of the liability as of the extinguishment date of $17.5 million related to the Series C Warrants and the $7.9 million in cash returned to the Note holders to extinguish the liability.

The Company had agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions were met, the installment payment was, at the election of the Company, automatically converted into shares of Common Stock at a conversion rate defined in the SPA. If the Company could not meet the equity conditions, it would have been required to repay some or all of the amounts due under the notes in cash. At any time after the issuance of the Notes, the Notes were convertible at the election of the holder into shares of our Common Stock at a conversion price equal to $8,537,775, subject to adjustment as provided in the Notes.

As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which was being amortized over the life of the Notes using the effective interest method. As of December 31, 2017, $35.0 million of the debt discount has been amortized to interest expense. All debt issuance costs were accounted for as a deferred asset and were amortized over the life of the Notes. As of December 31, 2017, the Company had incurred approximately $2.2 million in debt issuance costs all of which were amortized or expensed as of December 31, 2017.

Restructuring Agreement

On August 28, 2017, the Company entered into a Restructuring Agreement (the “Agreement”) with one of the institutional investors (the “Investor”) who was a party to the SPA. As of the date the Agreement was entered into, the Investor held $11,444,637 aggregate principal amount of Notes of which there was $10,092,857 aggregate Restricted Principal, (as defined in the Notes) of Notes (the “Restricted Notes”), secured by such aggregate cash amount held in a collateral account of the Company in the same amount (the “Restricted Cash”) and (y) $1,351,780 principal of Notes (the “Unrestricted Notes”), (ii) 4,200 shares of Series A Preferred Stock and (iii) 2,006 shares of Series B Convertible Preferred Stock.

Pursuant to the Agreement, (a) on the date thereof the Company and the Investor took the following actions (the “Initial Restructuring”): (i) the Investor released restrictions on $1,650,000 of Restricted Cash (the “Initial Release”), (ii) the Investor consented to the use of additional Restricted Cash to effect redemptions of the Series A Preferred Shares and the Series B Preferred Shares, (iii) the Investor cancelled $1,200,000 aggregate principal of the Notes (such portion of the Notes, the “Cancellation Note”), (iv) the Company redeemed all the Series A Preferred Shares outstanding for a cash payment to the Investor of $4.20 and (v) the Company redeemed the Series B Preferred Shares for a cash payment to the Investor of $2,006,000 and (b) upon the consummation of a reverse stock split of our Common Stock of at least twenty to one (the “Reverse Stock Split Event”, and such date, the “Reverse Stock Split Date”) by September 15, 2017, the Company and the Investor shall have taken the following actions (the “Additional Restructuring”, and together with the Initial Restructuring, the “Restructuring”): (i) the Investor shall consent to the use of Restricted Cash to effect redemptions of $4,000,000 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Redemption Notes”), (ii) the Company shall redeem the Redemption Notes for a redemption price of $6,436,852.80 (the “Redemption Price”) and (iii) the Company shall exchange (the “Exchange”), pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, $2,436,852.80 aggregate Restricted Principal of the Restricted Notes (such portion of the Restricted Notes, the “Exchange Notes”, and together with the Redemption Notes, the “Restructured Notes”) for new warrants to purchase 114,286 shares of its Common Stock (the “New Warrants”, as exercised, the “New Warrant Shares”). The New Warrants expire on the 42 month anniversary of the date of issuance and bear an exercise price of $61,250 per share (which shall be adjusted to the new lower purchase price per share if there is a subsequent “down round” financing). The Investor, in lieu of an exercise of the New Warrants pursuant to a cash payment of the aggregate exercise price of the number of New Warrants being exercised, may exercise the New Warrants, in whole or in part, by electing instead to receive upon such exercise two shares and one hundred and twenty-five thousandths of a share of the Company’s Common Stock for each Warrant Share exercised pursuant to this provision. The transactions set forth herein were being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 144(d)(3)(ii) of the 1933 Act. As a result of not having effected a reverse stock split by September 15, 2017, the Additional Restructuring did not occur.

This transaction was accounted for as a debt settlement that resulted in extinguishment. As such, the $1.9 million difference between the fair value of the common shares issued and the $1.2 million debt settlement was recorded as a loss on debt settlement.

Amendment to Restructuring Agreement

As a result of the lack of requisite approval by Delcath stockholders for the Company’s proposed reverse stock split, the parties and the two investors in the Notes entered into an amendment to the August restructuring agreement on October 10, 2017 as follows: (i) on the date that the Company effects a reverse split of its common stock, (x) the Company will exchange, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, an aggregate principal amount of those notes equal to $279,015 for new warrants to purchase an aggregate of 127,551 shares of Common Stock, and the Company shall redeem all the Series C Preferred Shares then outstanding for a cash payment of $590,000 and (ii) upon the initial consummation, on or prior to December 15, 2017, by the Company of the offering contemplated by the registration statement on Form S-1 that was filed with the SEC on October 11, 2017 the following shall occur: (i) pursuant to Section 3(b) of the Restricted Notes, the Company shall be deemed (as adjusted downward by the Black-Scholes value of the warrants being issued in this offering) to have automatically, and irrevocably, adjusted the conversion price of the Notes to 200% of the purchase price of a share of our common stock in the offering contemplated by the registration statement, (ii) the maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018, (iii) until the earlier of (x) this maturity date and (y) the 75^th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period, (iv) the Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes and (v) the conversion floor price on the notes is $0.05 and not subject to adjustments. As a result of not consummating an S-1 offering by December 15, 2017, the actions contemplated in (ii) of this paragraph did not occur. This transaction resulted in the extinguishment of $0.3 million in debt in exchange for the issuance of warrants. The $2.3 million difference in the fair value of the issued warrants and the $0.3 million in extinguished debt was recorded as a loss on debt extinguishment.

November 2017 Exchange Agreement

On November 15, 2017, the Company entered into exchange agreements (“Exchange Agreement”) with each of the two investors from its June 2016 private placement of senior secured convertible notes as contemplated by the SPA. As of November 15, 2017, those investors held $11,157,970 aggregate principal amount of Notes. On November 15, 2017, the Company authorized a new series of senior secured convertible notes of the Company, in the aggregate original principal amount as set forth above (the “Exchange Notes”), which Exchange Notes convertible into shares of Common Stock in accordance with the terms of the Exchange Notes. Subject to the terms and conditions of the Exchange Agreements, the Company and the investors exchanged for (a) $10,562,425 aggregate principal amount of the Exchange Notes (the “New Notes”, and the shares of Common Stock issuable pursuant to the terms of the New Notes, including, without limitation, upon conversion or otherwise, collectively, the “New Conversion Shares”) and (b) warrants to purchase an aggregate of 14,000 shares of Common Stock at an initial exercise price of $1,225. The warrants have a five year term.

The New Notes had the following terms:

•

The initial conversion price was $750.00 per share for an optional conversion and at any time, an investor could have instead engaged in an alternate conversion for which the conversion price was 82% (75% if an event of default) of the lowest vwap for the Company’s common stock on the three trading days prior to and including the date of the conversion.

•

The obligation to prepay the New Notes was extended to March 31, 2018, except in the case of an event of default or change in control.

•

Assuming equity conditions as stated in the New Notes are met, the investors consented to release cash to the Company from the existing controlled accounts upon conversion of the New Notes.

The November Exchange Agreement was accounted for as an extinguishment. As such, the New Notes were recorded at their calculated fair value of $15.2 million, the related November 2017 Warrants were recorded as a derivative liability at their calculated fair value of $14.4 million and the difference between the fair value of the New Notes, the fair value of the warrants issued, and the carrying amount of the old notes was recorded as a $19.0 million loss on extinguishment. As with the Notes issued in June 2016, the New Notes also contained a beneficial conversation feature. The value of this feature was considered in the fair value calculations of the New Notes and was determined to be $4.9 million of the $15.2 million total fair value. The $10.3 million fair value of the New Notes was accreted up to the face value of $10.6 million over the term of the New Notes with the $0.3 million difference charged to interest expense. The $4.9 million beneficial conversion feature was fully credited to Additional paid-in capital as the New Notes were fully satisfied under the December 28, 2017 Exchange Agreement. The November 2017 Warrants that were issued in connection with the November Exchange Agreement assessed at the end of each reporting period with any changes in fair value being recognized as derivative income or expense.

December 28, 2017 Exchange Agreements

On December 28, 2017, the Company entered into exchange agreements (“Exchange Agreements”), with each of the two investors from its June 2016 private placement of senior secured convertible notes (as further exchanged, the “Notes”) originally issued pursuant the SPA. Pursuant to the Exchange Agreements, the Company (i) extinguished its remaining $3,027,408 in outstanding obligations under the New Notes in full, (ii) obtained a release of restrictions on $2,046,898 in restricted cash held in its control accounts, (iii) issued to the investors 29,600 shares (the “Shares”) of its common stock and rights (“Rights”) to receive 217,800 shares of common stock to the extent such issuance of Shares would otherwise result in the beneficial ownership by any such investor of more than 4.9% or 9.9% of its issued and outstanding stock), as applicable, for an aggregate of 247,417 shares of its common stock (in each case, subject to trading restrictions set forth in leak out agreements the Company separately entered into with each) and (iv) a cash payment to the investors of $829,831 from the restricted cash held in the control accounts. The 29,600 shares were issued and outstanding at December 31, 2017. The rights were fully exercised in January 2018. This transaction resulted in the settlement of $3.0 million in debt. The $3.7 million difference between the fair value of the shares and rights issued for shares and the carrying value of the Notes was recorded as a loss on debt settlement.

The Company has issued shares of Common Stock and Preferred Stock as payments of principal (including certain early repayments at the option of the holders) and effected a retirement under the Notes and New Notes as follows:


	Number of Shares of Common Stock		Number of Shares of Preferred Stock		Applicable Conversion Price		Reduction in Principal
January 12, 2017		23		—	$	63,000.00	$	1,478,318
January 26 - February 1, 2017¹		10		—	$	56,000.00	$	544,000
February 10, 2017		87		—	$	35,000.00	$	3,045,817
February 23 - March 2, 2017¹		5		—	$	24,500.00	$	125,999
March 13, 2017		229		—	$	19,250.00	$	4,417,829
April 10, 2017		344		—	$	10,500.00	$	3,621,286
May 9, 2017		218		—	$	8,750.00	$	1,913,915
June 7 / July 2, 2017 Exchange Agreement²		1,380		4,200	$	12,250.00	$	4,200,000
July 7, 2017		229		—	$	12,250.00	$	2,000,000
August 4, 2017		83		—	$	5,250.00	$	1,015,848
August 28, 2017 Restructuring Agreement³		229		—	$	5,250.00	$	1,200,000
November 6, 2017 Warrant Exchange⁴		—		—	$	—	$	279,016
November 15, 2017 Exchange Agreements⁵		194,896		—	$	41.72	$	8,130,564
Retirement per December 28, 2017 Exchange Agreements⁶		—		—	$	—	$	553,234
December 28, 2017 Exchange Agreements⁶		445,152		—	$	10.00	$	2,474,174

Total		642,885					$	35,000,000

1	During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof.

On July 2, 2017, the Company entered into an exchange agreement with one of its investors which had purchased Notes, for $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock. The Series A Preferred Stock shares were issued to address a short-term valuation issue for 1,380 common shares delivered to the Notes holders to close an installment period. Through the Series A Preferred Shares placement, the Company was able to value the open installment shares such that the amount of debt remaining under the Notes was reduced by $4.2 million. Additionally, the Company recognized a loss on debt settlement of $1.0 million related to this transaction.

On August 28, 2017, the Company entered into a restructuring agreement with one of its investors which had purchased Notes. The restructuring agreement included a provision to exchange 229 shares for $1.2 million aggregate principal amount of such Notes. Additionally, the Company recognized a loss on debt settlement of $1.9 million related to this transaction.

4	On October 10, 2017, the Company entered into an amendment to the August 28, 2017 Restructuring Agreement which included a provision to exchange debt for the issuance of warrants. Additionally, the Company recognized a loss on debt extinguishment of $2.3 million.

On November 15, 2017, the Company entered into an exchange agreement which included a provision to exchange 1,948 shares for $0.6 million aggregate principal amount of such Notes. Additionally, the Company issued 192,948 million shares for $7.5 million aggregate principal amount of Notes under the updated conversion price formula as discussed in more detail above. Additionally, the Company recognized a loss on debt extinguishment of $21.0 million in connection with the issuance of the New Notes and warrants as part of such exchange.

On December 28, 2017, the Company entered into an exchange agreement to retire $0.6 million aggregate principal amount of Notes and to issue 247,417 million shares and rights for shares for the remaining $2.5 million aggregate principal amount of Notes. Additionally, the Company recognized a loss on debt extinguishment of $3.7 million.

Stockholders' Equity

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Stockholders Equity Note Abstract

Stockholders' Equity

(7)

Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On May 2, 2018, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-five hundred (1:500) split-adjusted basis. All owners of record as of the open of the OTCQB market on May 2, 2018 received one issued and outstanding share of Delcath common stock in exchange for five hundred outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-five hundred exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Quarterly Report on Form 10-Q and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

February 2018 Financing

In February 2018, the Company completed the sale of 424,000 shares of its common stock, 76,000 pre-funded warrants and the issuance of warrants to purchase 1.0 million common shares (the “February 2018 Warrants”) pursuant to a placement agent agreement, with net proceeds after expenses of $4.3 million. The February 2018 Warrants are exercisable one year after the anniversary date of their issuance. At March 31, 2018, the February 2018 Warrants were exercisable at $10.00 per share with 1.0 million warrants outstanding. The Company allocated an estimated fair value of $18.3 million to the February 2018 Warrants. The Company valued the February 2018 Warrants using the following inputs: exercise price of $10.00; contractual term of six years; volatility of 122.68% and risk free rate of approximately one percent. Due to certain price protection features in the agreement, the February 2018 Warrants were accounted for as a derivative liability at issuance and will be subsequently marked to market through the statement of operations.

Stock Incentive Plans

As a result of the May 2, 2018 reverse stock split, the Company’s Stock Incentive Plans have no active grants and no further shares available to be granted.

For the three months ended March 31, 2018, the Company recognized compensation expense of approximately $7,000 relating to stock options granted to employees. For the same period in 2017, the Company recognized compensation expense of approximately $21,000.

For the three months ended March 31, 2018, the Company recognized compensation expense of approximately $14,000 relating to restricted stock granted to employees. For the same period in 2017, the Company recognized compensation expense of approximately $27,000.

(10)

Stockholders’ Equity

Reverse Stock Split

On November 6, 2017, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-three hundred and fifty (1:350) split-adjusted basis. All owners of record as of the open of the OTCQB market on November 6, 2017 received one issued and outstanding share of Delcath common stock in exchange for three hundred and fifty issued and outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by theone-for-three hundred and fifty exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range ofone-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split.

In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares.

Preferred Stock Issuances

Series A Preferred Stock

On June 29, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series A Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series A Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series A Preferred Stock”). On July 2, 2017, the Company entered into an exchange agreement (the “Exchange”) with one of its investors which had purchased the Notes of $4.2 million aggregate principal amount of such Notes for 4,200 shares of Series A Preferred Stock (the “Series A Preferred Shares”). The Exchange was made in reliance upon the exemption from registration provided by Rule 3(a)(9) of the Securities Act of 1933, as amended. The Series A Preferred Shares were entitled to the whole number of votes equal to $4.2 million divided by $644,000.00 (the closing bid price on June 13, 2016, the date of issuance of the Notes) or 7 votes. The Series A Preferred Stock had no dividend, liquidation or other preferential rights to the Company’s common stock, and each share of Series A Preferred Stock was redeemed for the amount of $0.001, paid in cash pursuant to the Restructuring Agreement signed on August 28, 2017 and discussed in further detail in Note 9.

Series B Preferred Stock

On June 29, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series B Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock (the “Series B Certificate of Designations”) which was filed with the State of Delaware on June 30, 2017 (together with any preferred shares issued in replacement thereof in accordance with the terms thereof, the “Series B Preferred Stock”). On July 11, 2017, the Company entered into a securities purchase agreement with existing holders of Notes pursuant to which the investors purchased $2,360,000 of Series B Preferred Stock for a cash purchase price of $2,000,000 in a private placement. The Series B Preferred Stock was entitled to the whole number of votes equal to $2.0 million divided by $32,787 (the closing bid price on July 5, 2017, the date of the original securities purchase agreement for the Series B Preferred Stock), or 61 votes. The Series B Preferred Stock had no liquidation or other preferential rights (but had the redemption rights described below) to the Company’s common stock and could have been converted into shares of common stock at a price equal to $26,775 per share upon the earlier of the date of closing to the extent that the holder thereof reallocated shares of our common stock reserved for issuance under its Notes to conversion of the Series B Preferred Shares and otherwise upon receipt of shareholder approval of the Reverse Stock Split. The Series B Preferred Stock allowed for optional redemption by the Company at any time after issuance or the holders at any time after the tenth business day prior to the maturity date. In the instance of a Financing, the Company was required to redeem the Series B Preferred Stock. The $360,000 difference between the redemption amount and the cash purchase price of the Series B Preferred Stock, as well as all issuance costs related to the Series B Preferred Stock, have been recorded as a deemed dividend. The Series B Preferred Stock was redeemed for $2,360,000 pursuant to the Restructuring Agreement signed on August 28, 2017 with one investor and upon a redemption notice from the second investor as discussed in further detail in Note 9.

Series C Preferred Stock

On September 12, 2017, the Company’s Board authorized the establishment of a new series of preferred stock designated as Series C Preferred Stock, $0.01 par value, the terms of which are set forth in the certificate of designations for such series of Preferred Stock which was filed with the State of Delaware on September 20, 2017. On September 21, 2017, the Company entered into a securities purchase agreement with the two investors which had purchased Notes of $0.5 million aggregate purchase price for 590 shares of Series C Preferred Stock. The purchase of the Series C Preferred Stock is being made in reliance upon the exemption from registration provided by Rule 4(a)(2) of the Securities Act of 1933, as amended. The Series C Preferred Stock shall be entitled to 2,968 votes and may only vote on approval of a reverse split of our outstanding common stock. The Series C Preferred Stock has no dividend, liquidation or other preferential rights to the Company’s common stock, and each share of Series C Preferred Stock shall be redeemable for the amount of $1,000.00, payable in cash per share at our written election, and must be redeemed no later than December 21, 2017. Because the Series C Preferred Stock was mandatorily redeemable, it has been recorded as a liability with the difference between the purchases price and the fair value being recognized over the term of the instrument. Additionally, all expenses related to the issuance of the Series C Preferred Stock are recognized as a debt discount and have been amortized over the term of the instrument. Per the terms of the October 22, 2017 Amendment to the Restructuring Agreement, the Series C Preferred Stock was redeemed for $590,000 on November 6, 2017.

Stock and Warrant Issuances

In October 2013, the Company completed the sale of 1 share of its common stock and the issuance of warrants to purchase approximately 9 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2017, the 2013 Warrants were exercisable at $19,712,000 per share with 9 warrants outstanding. The 2013 Warrants have a five-year term.

In February 2015, the Company completed the sale of 1 share of its common stock and the issuance of warrants to purchase 9 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2017, the February 2015 Warrants were exercisable at $24,500 per share with approximately 9 warrants outstanding. The February 2015 Warrants have a five-year term.

In July 2015, the Company completed the sale of approximately 3 Units consisting of 3 shares of its common stock, Series A Warrants to purchase up to approximately 8 common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 3 common shares (“Series B Warrants”) and 8 Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the year ended December 31, 2016, approximately 1 Series B Warrant was exercised for net proceeds of approximately $0.8 million. The remaining 3 Series B Warrants expired on January 29, 2016 and the related liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 1 Series A Warrant was issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2017, the July 2015 Series A Warrants were exercisable at $24,500 with approximately 9 warrants outstanding. The Series A Warrants have a five-year term. There was approximately 1 July 2015 Series A Warrant exercised during the year ended December 31, 2017 for proceeds of approximately $15,000. There was approximately 1 July 2015 Series A Warrants exercised during the year ended December 31, 2016 for proceeds of $0.4 million.

In June 2016, the Company entered into a SPA pursuant to which the Company issued $35.0 million in principal face amount of the Notes and related Series C Warrants to purchase 40 additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. Pursuant to the Warrant Repurchase Agreements, each investor agreed to a Controlled Account Release, in an aggregate amount equal to $7.9 million, which funds in each case are to be paid to the respective investor, in exchange for cancellation of the Series C Warrants issued to each investor under the SPA. During 2017, 224,000 common shares and rights to receive 217,800 common shares were issued to satisfy the Notes.

In October 2016, the Company completed the sale of 2 shares of its common stock and the issuance of warrants to purchase 1 common share (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2017, the October 2016 Warrants were exercisable at $24,500 per share with 1 warrant outstanding. The October 2016 Warrants have a five-year term. There was 1 October 2016 Series C Warrants exercised during the year ended December 31, 2016 for proceeds of $0.1 million.

Pursuant to the October 10, 2017 Amendment to the Restructuring Agreement, 225 warrants were issued to each of the two investors from the June 2016 SPA on November 6, 2017 following the effectuation of the reverse stock split discussed earlier. The warrants contain a cashless exercise provision that allows the holders to exercise each warrant for three shares of common stock. The warrants have a 4.5 year term and an exercise price of $61,250. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. As of December 31, 2017, 255 warrants have been exercised resulting in the issuance of 735 common shares. 10 warrants remain outstanding at December 31, 2017.

In November 2017, the Company issued 14,049 warrants pursuant to an Exchange Agreement entered into with each of the two investors from the June 2016 SPA. The Company allocated an estimated fair value of $14.4 million to the November 2017 Warrants. The exercise price is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2017, the November 2017 Warrants were exercisable at $1,225 per share with 14,049 warrants outstanding. The November 2017 Warrants have a five-year term from the date of exercisability.

In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $71.8 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. The Company is not currently eligible to use its Form S-3.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 0 and 0 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 0 shares, from 0 to 0 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of December 31, 2017, there were 0 shares available to grant under the 2009 Stock Incentive Plan.

A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant.

Stock option activity for 2017, 2016 and 2015 is as follows:


	Stock Option Activity under the Plans⁽¹⁾
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2014		0		$	0 - $0	$	0		0
Granted		0			0		0		0
Forfeited		(0	)		0-0		0		0

Outstanding at December 31, 2015		0		$	0 - $0	$	0		0
Granted		—			—		—
Forfeited		(0	)		0-0		0		0

Outstanding at December 31, 2016		0		$	0 - $0	$	0		0
Granted		0		$	0	$	0		0
Forfeited		(0	)	$	0	$	0		0

Outstanding at December 31, 2017		0		$	0 - $0	$	0		0

Exercisable at December 31, 2017		0		$	0 - $0	$	0		0

(1)	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

For the years ended December 31, 2017, 2016 and 2015 the Company recognized compensation expense related to stock option grants of approximately $0.1 million, $0.2 million and $0.3 million, respectively.

The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants made in 2017 and 2015. There were no option grants during 2016.


	Year ended December 31,			Year ended December 31,
	2017			2015
Weighted average risk-free interest rates		2.15	%		1.82	%
Weighted average expected volatility		170.42	%		97.70	%
Dividend yield		—			—
Weighted average expected option term (in years)		7.29			5.15
Weighted average grant date fair value	$	82.34		$	4,964.73

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term is based on actual historical results.

A summary of the Company’s non-vested options to purchase shares as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below:


	Non-Vested Options⁽¹⁾
	Number of Options			Weighted Average Exercise Price
Non-vested at December 31, 2015		0		$	0
Granted		—			—
Vested		(0	)		0
Forfeited		(0	)		0

Non-vested at December 31, 2016		0		$	0
Granted		0			0
Vested		(0	)		0
Forfeited		(0	)		0

Non-vested at December 31, 2017		0		$	0

Additional compensation expense of approximately $6,800, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 0.42 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2017 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $450.00 as of December 31, 2017, which would have been received by the option holders had those option holders exercised their options as of that date.

A summary of the Company’s restricted stock activity as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below:


	Restricted Stock Activity⁽¹⁾
	Number of Shares		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2015		—	$	—
Granted		—		—
Vested		—		—
Forfeited		—		—

Non-vested at December 31, 2016		—	$	—
Granted		—		—
Vested		—		—
Forfeited		—		—

Non-vested at December 31, 2017		—	$	—

For the three years ended December 31, 2017, 2016 and 2015 the Company recognized compensation expense related to restricted stock grants of approximately $0.1 million, $0.3 million and $0.3 million, respectively.

(1)	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Warrants

The Company issued warrants as part of its offerings in 2013, 2015, and 2016 as well as part of its issuance of convertible notes in 2016 and an exchange agreement in 2017. A summary of warrant activity is as follows:


	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at January 1, 2014		9		$	4,900,000-$19,712,000	$	15,170,879		2.78
Issued		35					2,240,000
Exercised		(-	)				2,296,000
Expired		(-	)				2,296,000

Outstanding at December 31, 2015		44		$	2,072,000-19,712,000	$	44,858,633		2.16

Issued		30					840,000
Exercised		(3	)				481,250
Expired		(3	)				994,000

Outstanding at December 31, 2016		78		$	281,750-$19,712,000	$	910,000		5.59
Issued		14,256					2,299
Exercised		(246	)				4,221
Expired		(39	)				845,250

Outstanding at December 31, 2017		14,049		$	1,225-19,712,000	$	1,569		4.88

Fair Value Measurements

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

(8)

Fair Value Measurements

Derivative Warrant Liability

For the three months ended March 31, 2018, the Company recorded derivative warrant income of $14.7 million. The resulting derivative warrant liabilities totaled $4.2 million at March 31, 2018. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at March 31, 2018 and December 31, 2017 was determined by using option pricing models with the following assumptions:


	March 31, 2018	December 31, 2017
Expected life (in years)	0.58 - 5.87	0.82 - 4.88
Expected volatility	122.68% - 291.61%	130.88% - 266.92%
Risk-free interest rates	1.95% - 2.63%	1.68% - 2.06%

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2018, aggregated by the level in the fair value hierarchy within which those measurements fall in accordance with ASC 820.


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1		Level 2		Level 3		Balance at March 31, 2018
Liabilities
Derivative instrument liabilities	$	—	$	—	$	4,169	$	4,169

For the periods ended March 31, 2018 and 2017, there were no transfers in or out of Level 1, 2 or 3 inputs.

The table below presents the activity within Level 3 of the fair value hierarchy for the three months ended March 31, 2018:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at December 31, 2017	$	560
Fair value of warrants issued		18,306
Fair value of warrants exercised		—
Total change in the liability included in earnings		(14,697	)

Balance at March 31, 2018	$	4,169

(11)

Fair Value Measurements

Derivative Financial Instruments

As disclosed in Note 10 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes and allocated an estimated fair value of $14.4 million to warrants issued pursuant to an exchange agreement signed in November 2017 discussed in further detail in Note 9 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K. The valuations of the October 2013, February 2015, July 2015 Series A, October 2016 and November 2017 Warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

For the year ended December 31, 2017, the Company recorded pre-tax derivative instrument income of $15.1 million. The resulting derivative instrument liabilities totaled $0.6 million at December 31, 2017. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2017 was determined by using option pricing models assuming the following:


	November 2017 Warrants			October 2016 Warrants			July 2015 Series A Warrants			February 2015 Warrants			October 2013 Warrants
Expected volatility		217.39	%		130.88	%		161.87	%		169.95	%		266.92	%
Risk free interest rates		1.98	%		2.06	%		1.94	%		1.90	%		1.68	%
Expected life (in years)		4.88			3.76			2.56			2.13			0.82

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2017 and 2016, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Level 1				Level 2				Level 3				Balance at December 31,
(in thousands)	2017		2016		2017		2016		2017		2016		2017		2016
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	560	$	18,751	$	560	$	18,751

Fair Value Measurements Using Significant Unobservable

Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at January 1, 2015	$	225
Total change in the liability included in earnings		(564	)
Fair value of warrants issued		4,247
Fair value of warrants exercised		(123	)

Balance at December 31, 2015		3,785
Total change in the liability included in earnings		(12,780	)
Fair value of warrants issued		28,472
Fair value of warrants exercised		(726	)

Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(15,103	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		16,953
Fair value of warrants exercised		(2,552	)

Balance at December 31, 2017	$	560

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Commitments

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments

(12)

Commitments

Operating Leases

In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space at 810 Seventh Avenue, New York, NY with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $996,000 in 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space.

In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August, 2011. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The remaining annual lease amount is (USD conversion is based on the December 31, 2017 conversion rate):– €183,179 ($143,726). Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath. The Company has sub-leased a portion of this facility.

In March 2016, the Company entered into a sub-lease agreement to lease approximately 6,877 square feet of office space at 1633 Broadway, New York, NY. The term began in April 2016 and is effective through March 2019. The agreement provides for total annual base rent of $522,652.

In October 2016, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2016 and was effective for a two year period. The agreement provides for total annual base rent of $48,223 and will expire October 2018.

Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2017 are as follows:


(in thousands)	Future Lease Payment
2018		872
2019		501
2020		456
2021		281
2022		—
2023		—

	$	2,110

For the years ended December 31, 2017, 2016, and 2015 rent expense totaled approximately $0.6 million, $0.5 million and $0.4 million, respectively.

Letters of Credit

Under the terms of the lease agreement for office space at 810 Seventh Avenue, New York, NY, the Company is required to maintain a letter of credit in the amount of $881,297 which will expire in February 2019 if not renewed by the Company. Under the terms of a sub-lease agreement for office space at 1633 Broadway, New York, NY, the Company is required to maintain a letter of credit in the amount of $130,663 which will expire with the sublease in March 2019.

Taxes

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Taxes

(10)

Taxes

As discussed in Note 13 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected us, including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We were required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. Since the Tax Act was passed late in the fourth quarter of 2017, and ongoing guidance and accounting interpretation are expected over the next 12 months, we consider the accounting of deferred tax re-measurements and the transition tax to be incomplete due to the forthcoming guidance and our ongoing analysis of final year-end data and tax positions. However, we were able to determine a provisional amount of $143,500 (offset by valuation allowance) and $0, respectively, related to the deferred tax re-measurement and one-time transition tax (additional detail is provided in Note 13 Income Taxes of the Company’s Annual Report). As of March 31, 2018, a SAB 118 measurement period adjustment has not been recorded, as the Company is continuing to assess the impact from the Tax Act and will record adjustments in 2018 if necessary.

In October 2016, the Financial Accounting Standards Board (“FASB”) issued accounting standards update 2016-16 which simplifies the income tax consequences of intra-entity transfers other than inventory. Prior to ASU 2016-16, GAAP prohibited the recognition of current and deferred income taxes for intra-entity asset transfers until the asset has been sold to an outside party. ASU 2016-16 eliminates this prohibition for intra-entity transfers of assets other than inventory but retain the prohibition for intra-entity transfers of inventory. This standard is effective for public entities for fiscal years beginning after December 15, 2017. The Company adopted ASU 2016-16, effective on January 1, 2018. As a result of adoption, the Company recognized a $834 decrease to its net operating loss deferred tax assets, offset by a $834 decrease to the corresponding valuation allowance.

(13)

Income Taxes

There is no income tax provision for the years ended December 31, 2017, 2016 and 2015.

Income (loss) before income taxes consists of:


	Year Ended December 31,
(in thousands)	2017			2016			2015
Domestic	$	(41,313	)	$	(13,930	)	$	(11,276	)
Foreign		(3,804	)		(4,040	)		(3,428	)

Income (loss) before taxes	$	(45,117	)	$	(17,970	)	$	(14,704	)

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:


	Year Ended December 31,
(in thousands)	2017			2016			2015
Income taxes using U.S federal statutory rate	$	(15,340	)	$	(6,110	)	$	(4,999	)
Tax Cuts and Jobs Act		143			—			—
Nondeductible interest		6,912			—			—
Loss on extinguishment of debt		10,174
Loss of tax benefit of federal net operating loss carryforwards		5,067			68,795			—
Loss of tax benefit of state net operating loss carryforwards		1,373			13,891			—
Loss of tax benefit of federal tax credit carryforwards		324			4,023			—
Amortization of gain on IP migration		767			767			767
State income taxes, net of federal benefit		(1,339	)		(2,576	)		380
Foreign rate differential		1,196			1,141			920
Valuation allowance		(1,423	)		(75,407	)		2,649
Derivative charge		(8,403	)		(4,345	)		(192	)
Stock option exercises and cancellations		841			53			674
Research and development costs		(295	)		(250	)		(199	)
Other		3			18			—

	$	—		$	—		$	—

Significant components of the Company’s deferred tax assets are as follows:


	Year Ended December 31,
(in thousands)	2017		2016		2015
Deferred tax assets:
Employee compensation accruals	$	292	$	1,386	$	1,279
Accrued liabilities		353		343		633
Research tax credits		17		22		3,796
Other		34		55		66
Net operating losses		5,289		6,194		77,906

Total deferred tax assets		5,985		8,000		83,680

Deferred tax liabilities:
Beneficial conversion feature		—		906		—
Other		13		—		—
Total deferred tax liabilities		13		906		—

Valuation allowance		5,972		7,094		83,680

Net deferred tax assets	$	—	$	—	$	—

As of December 31, 2017, 2016 and 2015, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $211.3 million, $209.3 million and $184.5 million, respectively. A significant portion of the federal amount, $210.5 million, is subject to an annual limitation of approximately $27,500 as a result of a changes in the Company’s ownership in May 2003, November 2016 and multiple dates throughout 2017, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitations caused by the May 2003, November 2016 and multiple 2017 ownership changes, approximately $209.5 million of the total net operating loss carryforwards is expected to expire unutilized and will be unavailable to offset future federal taxable income. Approximately $1.0 million of net operating loss carryforwards remains available to offset future federal taxable income which will expire between 2018 and 2037. In addition, the Company’s state net operating losses are also subject to annual limitations that generally follow the federal Section 382 provisions (with the exception of Connecticut), adjusted for each state’s respective income apportionment percentages. As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for state and city income tax purposes between approximately $27.3 million and $150.3 million and between approximately $27.3 million and $153.0 million, respectively, which expire through 2037. As a result of the 382 limitations, approximately $149.0 million and $133.3 million of New York State and New York City net operating losses are expected to expire unutilized and will be unavailable to offset future taxable income. Approximately $0.8 million and $0.8 million of net operating loss carryforwards, respectively, will be available to offset future state and city taxable income. As of December 31, 2017, 2016 and 2015, the Company had a net operating loss carryforward for foreign income tax purposes of $25.0 million, $21.1 million and $22.1 million, respectively, which have indefinite carryforward periods. As of December 31, 2017, 2016 and 2015, the Company had federal research and development tax credit carryforwards of approximately $4.3 million, $4.0 million and $3.8 million, respectively, which expire through 2037. As a result of the section 382 limitation, the entire tax credit carryforward is expected to expire unutilized.

Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance decreased by approximately $1.1 million and $76.6 million in 2017 and 2016, respectively. The primary reason for the significant decrease in the valuation allowance during 2016 is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows:


(in thousands)	December 31, 2017			December 31, 2016
Beginning balance	$	7,094		$	83,680
Charged to costs and expenses		(1,423	)		(75,407	)
Charged to additional paid-in capital		—			(1,854	)
Charged to retained earnings		—			1,010
Charged to other comprehensive income		301			(335	)

Ending balance	$	5,972		$	7,094

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”). The Act, which is also commonly referred to as “U.S. tax reform”, significantly changes U.S. corporate income tax laws by, among other provisions, reducing the maximum U.S. corporate income tax rate from 35% to 21% starting in 2018. At December 31, 2017, the Company has not completed its accounting for the tax effects of enactment of the Act; however, as described below, the Company has made a reasonable estimate of the effects on its existing deferred tax balances and the one-time transition tax. The Company is continuing to assess the impact from the Act and will record adjustments in 2018 if necessary.

During the year ended December 31, 2017, the Company reduced deferred tax assets by a provisional amount of $143,500, offset by a corresponding reduction to its valuation allowance, as a result of the re-measurement of deferred tax assets and liabilities from its 34% effective rate under existing law to the new lower statutory rate of 21%. However, the Company is still analyzing certain aspects of the Act and refining its calculations, which could potentially affect the measurement of these balances or potentially give rise to new deferred tax amounts.

The Act also requires a mandatory one-time inclusion of the deferred foreign income of controlled foreign corporations. The one-time transition tax is based on Delcath’s total post-1986 earnings and profits (E&P) for which the Company has previously deferred from U.S. income taxes. The Company’s reasonable estimate resulted in no provisional amount for the one-time transition tax liability, as the Company’s international subsidiaries are expected to have a cumulative deficit in E&P. Delcath has not yet completed its calculation of the total post-1986 foreign E&P (including deficits) for these foreign subsidiaries. As the Company’s international subsidiaries have a cumulative deficit in earnings and profits, the Company does not anticipate being affected by the mandatory inclusion provisions of the Act.

On December, 22, 2017, SAB 118 was issued due to the complexities involved in accounting for the recently enacted Act. SAB 118 requires the Company to include in its financial statements a reasonable estimate of the impact of the Act on earnings to the extent such estimate has been determined. Accordingly, the U.S. provision for income tax for 2017 is based on the reasonable estimate guidance provided by SAB 118. The Company is continuing to assess the impact from the Act and will record adjustments in 2018 if necessary.

The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10 and therefore has not included a tabular rollfoward of unrecognized tax benefits. As there are no uncertain tax positions recognized, interest and penalties have not been accrued.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. During the third quarter of 2015, the Internal Revenue Service commenced an examination of the Company’s federal income tax return for the year ended December 31, 2013. The examination was completed in the third quarter of 2017 and no changes were made to the reported amounts. Accordingly, there was no effect on the financial statements as a result of the examination. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company is no longer subject to federal and state examination for tax years ending prior to December 31, 2014; tax years ending December 31, 2014 through December 31, 2017 remain open to examination. The Republic of Ireland is the Company’s only significant foreign jurisdiction. The Company is no longer subject to Ireland tax examination for tax years ending prior to December 31, 2013 (as Ireland has not initiated an audit of 2012 as of December 31, 2017); tax years ending December 31, 2013 through December 31, 2017 remain open to examination. However, the Company’s tax years December 31, 1998 through December 31, 2017 generally remain open to adjustment for all federal, state and foreign tax matters until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization, and the applicable statutes of limitation have expired in the utilization year. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

(14)

Quarterly Financial Data (Unaudited)

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2017 and 2016.


	2017 Quarters Ended
(in thousands, except per share amounts)	March 31			June 30			September 30			December 31
Revenue	$	743		$	584		$	684		$	704
Costs and expenses		4,736			5,050			5,139			5,254
Operating loss		(4,212	)		(4,601	)		(4,627	)		(4,725	)
Net loss		(11,332	)		(1,943	)		(12,596	)		(19,246	)
Basic loss per share		43,750			1,750			4,680			375

	2016 Quarters Ended
(in thousands, except per share amounts)	March 31			June 30			September 30			December 31
Revenue	$	370		$	511		$	435		$	676
Costs and expenses		3,721			4,232			5,047			4,882
Operating loss		(3,462	)		(3,871	)		(4,724	)		(4,383	)
Net loss		(1,813	)		(6,667	)		(1,004	)		(8,486	)
Basic loss per share		218,750			771,750			115,495			646,010

Subsequent Events

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Subsequent Events [Abstract]

Subsequent Events

(11)

Subsequent Events

The Company completed its Consent Solicitation in lieu of a Special Meeting of Shareholders on April 6, 2018 and reported that both a proposal to approve an amendment to our amended and restated certificate of incorporation to increase our authorized shares of common stock from 500,000,000 to 1,000,000,000 and a proposal to approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock at a range of ratios from 1-for-100 to 1-for-500, in the discretion of the Board of Directors and to be announced by press release, and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing (but not later than April 6, 2019) were approved by shareholders.

On May 2, 2018, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-five hundred (1:500) split-adjusted basis. All owners of record as of the open of the OTCQB market on May 2, 2018 received one issued and outstanding share of Delcath common stock in exchange for five hundred outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-five hundred exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Prospectus and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

On June 4, 2018, pursuant to a Securities Purchase Agreement (“Securities Purchase Agreement”) between the Company and a non-U.S. person institutional investor (“Investor”), the Company sold two 8% Senior Secured Convertible Promissory Notes (“Notes”) for a total face amount of $3,886,109 and a purchase price of $2,270,463 to the Investor in a transaction exempt from registration under Regulation S, as amended promulgated under the Securities Act of 1933.

(15)

Subsequent Events

As of January 25, 2018, all of the Rights issued under the December 28, 2017 Exchange Agreements discussed in more detail in Note 9 to the Company’s consolidated financial statements contained in this Annual Report on Form 10-K have been exercised resulting in the issuance of 108.9 million shares.

On February 9, 2018, the Company closed a registered offering of 212,000,000 shares of common stock, 38,000,000 pre-funded warrants to purchase 38,000,000 shares of common stock and Series D warrants to purchase an aggregate of 500,000,000 shares of common stock for total gross proceeds of approximately $5.0 million. The offering was priced at $0.02 per unit with each unit comprised of one share of common stock (or one pre-funded warrant) and one common stock purchase warrant to purchase two shares, provided that, with respect to the units with pre-funded warrants $0.019 per unit shall be paid at closing and $0.001 shall be paid upon exercise of each of the pre-funded warrants. The warrants carry a five-year term from the date of initial exercisability (which is later of one year from the date of issuance and date of amendment to articles of incorporation to increase number of authorized shares of common stock) with an exercise price of $0.02 per share. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-220898) previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on February 7, 2018. After consummation of this offering, the Company has 434,981,824 shares of its common stock issued and outstanding.

On February 26, 2018, the Company filed a Definitive Proxy Statement on Schedule 14A seeking shareholder approval to increase its authorized shares of common stock from 500,000,000 to 1,000,000,000 in order to have sufficient authorized shares for full exercise of its recently issued Series D Warrants and for a reverse split of its common stock at a ratio of at least 1:100 but no more than 1:500, in the discretion of the Board of Directors and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing (but not later than April 6, 2019).

The Company increased its authorized shares of common stock to one billion and effected a reverse split of its issued and outstanding common stock in a ratio of one-for-five hundred, effective as of May 2, 2018.

On May 2, 2018, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-five hundred (1:500) split-adjusted basis. All owners of record as of the open of the OTCQB market on May 2, 2018 received one issued and outstanding share of Delcath common stock in exchange for five hundred outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-five hundred exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

General

3 Months Ended

Mar. 31, 2018

Net Loss per Common Share

General

(1)

General

The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three months ended March 31, 2018 and 2017 should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (“Annual Report”), which has been filed with the Securities Exchange Commission (“SEC”) on March 16, 2018 and can also be found on the Company’s website (www.delcath.com). In these notes the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

Description of Business

Our primary research focus is on ocular melanoma liver metastases (mOM), and intrahepatic cholangiocarcinoma (ICC), a type of liver cancer, and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need.

Our clinical development program for CHEMOSAT and Melphalan/HDS is comprised of The FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial), a Global Phase 3 clinical trial that is investigating overall survival in mOM, and a registration trial for intrahepatic cholangiocarcinoma (ICC) we plan to initiate in 2018. Our clinical development plan (CDP) also includes a commercial registry for CHEMOSAT non-clinical commercial cases performed in Europe and sponsorship of select investigator initiated trials (IITs) in colorectal cancer metastatic to the liver (mCRC) and pancreatic cancer metastatic to the liver.

Liquidity and Operating Matters

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $317.6 million at March 31, 2018. This deficit, among other factors raises substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all entities controlled by Delcath and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2018 and 2017; however, certain information and footnote disclosures normally included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

On May 2, 2018, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-five hundred (1:500) split-adjusted basis. All owners of record as of the open of the OTCQB market on May 2, 2018 received one issued and outstanding share of Delcath common stock in exchange for five hundred outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-five hundred exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

Significant Accounting Policies

A description of our significant accounting policies has been provided in Note 3 Summary of Significant Accounting Policies to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K filed for the period ended December 31, 2017.

Recently Adopted Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers.

On January 1, 2018, the Company adopted ASU 2014-09 using the modified retrospective method and the impact was determined to be immaterial on its consolidated financial statements. The new revenue standard was applied prospectively in Delcath’s condensed consolidated financial statements from January 1, 2018 forward and reported financial information for historical comparable periods will not be revised and will continue to be reported under the accounting standards in effect during those historical periods.

Delcath generates revenue from the sales of its product in Europe, where its system is commercially available under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (“CHEMOSAT^®”). Revenue from product sales is generally recognized at the time of shipment to a treating center or distributor, when control of the promised goods has been transferred to our customers. When obligations or contingencies remain after the products are shipped, such as training and certifying new treatment centers, revenue is deferred until the obligations or contingencies are satisfied.

Delcath has one distribution contract with a Turkish distributor. The contract has standard provisions for termination, renewal, limited warranty and right of return. CHEMOSAT kits are delivered to the Turkish distributor as orders are received and revenue is recognized at the time of shipment to the distributor. Delcath sells directly to centers in Europe with the exception of those centers located in Turkey. Sales are processed when purchase orders are received from the hospitals and revenue is recognized at the time of shipment to the treating center.

Recently Issued Accounting Pronouncements

Net Loss per Common Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

(9)

Net Loss per Common Share

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2018 and March 31, 2017 because their effects would be anti-dilutive:


	March 31,
	2018		2017
Warrants		1,014,041		41

Total		1,014,041		41

Summary of Significant Accounting Policies (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Liquidity and Operating Matters

Liquidity and Operating Matters

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has an accumulated deficit of $317.6 million at March 31, 2018. This deficit, among other factors raises substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.

Liquidity

Use of Estimates

Use of Estimates

Cash Equivalents and Concentrations of Credit Risk

Cash Equivalents and Concentrations of Credit Risk

Restricted Cash

Restricted Cash

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Property, Plant and Equipment

Property, Plant and Equipment

Derivative Instrument Liability

Derivative Instrument Liability

Fair Value Measurements

Fair Value Measurements

•

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

•

Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

Revenue Recognition

Revenue Recognition

Deferred Revenue

Deferred Revenue

Selling, General and Administrative

Selling, General and Administrative

Research and Development

Research and Development

Stock Based Compensation

Stock Based Compensation

Income Taxes

Income Taxes

Net Loss per Common Share

Net Loss per Common Share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows:


(in thousands, except share data)	2017			2016			2015
Net loss	$	(45,117	)	$	(17,971	)	$	(14,704	)
Preferred stock dividends		(527	)		—			—

Net loss, adjusted		(45,644	)		(17,971	)		(14,704	)
Net loss per share – basic and diluted		(3,250	)		(1,853,500	)		(2,548,000	)
Weighted average shares outstanding – basic and diluted		14,039			10			6

Shares excluded from the computation of diluted EPS:


	2017		2016		2015
Stock options		—		—		—
Unvested restricted shares		—		—		—
Warrants		14,049		41		65

Total		14,049		41		63

Segment Information

Segment Information

Foreign Currency and Currency Translation

Foreign Currency and Currency Translation

Recently Adopted and Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Recent Accounting Pronouncements

Basis of Presentation

Basis of Presentation

On May 2, 2018, the Company effected a reverse stock split at which time Delcath’s common stock began trading on the OTCQB on a one-for-five hundred (1:500) split-adjusted basis. All owners of record as of the open of the OTCQB market on May 2, 2018 received one issued and outstanding share of Delcath common stock in exchange for five hundred outstanding shares of Delcath common stock. No fractional shares were issued in connected with the reverse stock split. All fractional shares created by the one-for-five hundred exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Calculation of net loss and number of shares used to compute basic and diluted earnings per share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 are as follows:


(in thousands, except share data)	2017			2016			2015
Net loss	$	(45,117	)	$	(17,971	)	$	(14,704	)
Preferred stock dividends		(527	)		—			—

Net loss, adjusted		(45,644	)		(17,971	)		(14,704	)
Net loss per share – basic and diluted		(3,250	)		(1,853,500	)		(2,548,000	)
Weighted average shares outstanding – basic and diluted		14,039			10			6

Net Loss per Common Share (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from the computation of earnings per share

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2018 and March 31, 2017 because their effects would be anti-dilutive:


	March 31,
	2018		2017
Warrants		1,014,041		41

Total		1,014,041		41

Shares excluded from the computation of diluted EPS:


	2017		2016		2015
Stock options		—		—		—
Unvested restricted shares		—		—		—
Warrants		14,049		41		65

Total		14,049		41		63

Inventories (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Raw materials	$	275	$	298
Work-in-process		682		721
Finished goods		323		229

Total inventories	$	1,280	$	1,248

Inventories consist of:


(in thousands)	December 31, 2017		December 31, 2016
Raw materials	$	298	$	346
Work-in-process		721		214
Finished goods		229		100

Total Inventory	$	1,248	$	660

Prepaid Expenses And Other Current Assets (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Insurance premiums	$	337	$	421
Financing costs		—		70
VAT/GST receivable		34		29
Security Deposit		49		50
Other¹		134		130

Total prepaid expenses and other current assets	$	554	$	700

¹	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% of prepaid expenses and other current assets at March 31, 2018 and December 31, 2017.

Prepaid expenses and other current assets include the following:


(in thousands)	December 31, 2017		December 31, 2016
Insurance premiums	$	421	$	501
Financing costs		70		—
Security deposit		50		50
Other¹		159		147

Total prepaid expenses and other current assets	$	700	$	698

¹	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2017 and 2016.

Property, Plant, and Equipment (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consist of the following:


(in thousands)	March 31, 2018			December 31, 2017
Buildings and land	$	579		$	579
Enterprise hardware and software		1,746			1,744
Leaseholds		1,719			1,705
Equipment		971			971
Furniture		176			175

Property, plant and equipment, gross		5,191			5,174
Accumulated depreciation		(4,003	)		(3,876	)

Property, plant and equipment, net	$	1,188		$	1,298

Property, plant, and equipment consists of:


(in thousands)	December 31, 2017			December 31, 2016
Buildings and land	$	579		$	556
Enterprise hardware and software		1,744			1,532
Leaseholds		1,705			1,504
Equipment		971			940
Furniture		175			354

Property, plant and equipment, gross		5,174			4,886
Accumulated depreciation		(3,876	)		(3,803	)

Property, plant and equipment, net	$	1,298		$	1,083

Accrued Expenses (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:


(in thousands)	March 31, 2018		December 31, 2017
Compensation, excluding taxes	$	738	$	1,124
Clinical trial expenses		1,603		869
Professional fees		95		221
Short-term portion of lease restructuring		197		209
Other¹		893		985

Total accrued expenses	$	3,526	$	3,408

¹	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at March 31, 2018 and December 31, 2017.

Current accrued expenses include the following:


(in thousands)	December 31, 2017		December 31, 2016
Clinical trial expenses	$	869	$	1,365
Compensation, excluding taxes		1,124		933
Professional fees		221		286
Short-term portion of lease restructuring		209		216
Other¹		985		607

Total accrued expenses	$	3,408	$	3,407

Restructuring Expenses (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Schedule of restructuring and related costs

The following table provides the year-to-date activity of the Company’s restructuring reserves as of March 31, 2018:


(in thousands)	Lease Liability
Reserve balance at December 31, 2017	$	604
Charges		—
Payments/Utilizations		(58	)

Reserve balance at March 31, 2018	$	546

The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2017:


(in thousands)	Lease Liability
Reserve balance at December 31, 2016	$	820
Charges		—
Payments/Utilizations		(216	)

Reserve balance at December 31, 2017	$	604

Convertible Notes Payable (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure Abstract

Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes


	Number of Shares of Common Stock		Number of Shares of Preferred Stock		Applicable Conversion Price		Reduction in Principal
January 12, 2017		23		—	$	63,000.00	$	1,478,318
January 26 - February 1, 2017¹		10		—	$	56,000.00	$	544,000
February 10, 2017		87		—	$	35,000.00	$	3,045,817
February 23 - March 2, 2017¹		5		—	$	24,500.00	$	125,999
March 13, 2017		229		—	$	19,250.00	$	4,417,829
April 10, 2017		344		—	$	10,500.00	$	3,621,286
May 9, 2017		218		—	$	8,750.00	$	1,913,915
June 7 / July 2, 2017 Exchange Agreement²		1,380		4,200	$	12,250.00	$	4,200,000
July 7, 2017		229		—	$	12,250.00	$	2,000,000
August 4, 2017		83		—	$	5,250.00	$	1,015,848
August 28, 2017 Restructuring Agreement³		229		—	$	5,250.00	$	1,200,000
November 6, 2017 Warrant Exchange⁴		—		—	$	—	$	279,016
November 15, 2017 Exchange Agreements⁵		194,896		—	$	41.72	$	8,130,564
Retirement per December 28, 2017 Exchange Agreements⁶		—		—	$	—	$	553,234
December 28, 2017 Exchange Agreements⁶		445,152		—	$	10.00	$	2,474,174

Total		642,885					$	35,000,000

1	During the periods referenced above, the Company and the holders of the Notes agreed to a temporary reduction in the conversion price in order to encourage voluntary conversion of Notes by the holders thereof.

4	On October 10, 2017, the Company entered into an amendment to the August 28, 2017 Restructuring Agreement which included a provision to exchange debt for the issuance of warrants. Additionally, the Company recognized a loss on debt extinguishment of $2.3 million.

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders Equity Note Abstract

Stock option activity

Stock option activity for 2017, 2016 and 2015 is as follows:


	Stock Option Activity under the Plans⁽¹⁾
	Stock Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at December 31, 2014		0		$	0 - $0	$	0		0
Granted		0			0		0		0
Forfeited		(0	)		0-0		0		0

Outstanding at December 31, 2015		0		$	0 - $0	$	0		0
Granted		—			—		—
Forfeited		(0	)		0-0		0		0

Outstanding at December 31, 2016		0		$	0 - $0	$	0		0
Granted		0		$	0	$	0		0
Forfeited		(0	)	$	0	$	0		0

Outstanding at December 31, 2017		0		$	0 - $0	$	0		0

Exercisable at December 31, 2017		0		$	0 - $0	$	0		0

(1)	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Assumptions used to determine estimated fair value of stock options granted


	Year ended December 31,			Year ended December 31,
	2017			2015
Weighted average risk-free interest rates		2.15	%		1.82	%
Weighted average expected volatility		170.42	%		97.70	%
Dividend yield		—			—
Weighted average expected option term (in years)		7.29			5.15
Weighted average grant date fair value	$	82.34		$	4,964.73

Summary of restricted stock activity

A summary of the Company’s non-vested options to purchase shares as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below:


	Non-Vested Options⁽¹⁾
	Number of Options			Weighted Average Exercise Price
Non-vested at December 31, 2015		0		$	0
Granted		—			—
Vested		(0	)		0
Forfeited		(0	)		0

Non-vested at December 31, 2016		0		$	0
Granted		0			0
Vested		(0	)		0
Forfeited		(0	)		0

Non-vested at December 31, 2017		0		$	0

Summary of non-vested options

A summary of the Company’s restricted stock activity as of December 31, 2017 and changes during the years ended December 31, 2017 and December 31, 2016 are presented below:


	Restricted Stock Activity⁽¹⁾
	Number of Shares		Weighted Average Grant Date Fair Value
Non-vested at December 31, 2015		—	$	—
Granted		—		—
Vested		—		—
Forfeited		—		—

Non-vested at December 31, 2016		—	$	—
Granted		—		—
Vested		—		—
Forfeited		—		—

Non-vested at December 31, 2017		—	$	—

(1)	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Summary of warrant activity


	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)
Outstanding at January 1, 2014		9		$	4,900,000-$19,712,000	$	15,170,879		2.78
Issued		35					2,240,000
Exercised		(-	)				2,296,000
Expired		(-	)				2,296,000

Outstanding at December 31, 2015		44		$	2,072,000-19,712,000	$	44,858,633		2.16

Issued		30					840,000
Exercised		(3	)				481,250
Expired		(3	)				994,000

Outstanding at December 31, 2016		78		$	281,750-$19,712,000	$	910,000		5.59
Issued		14,256					2,299
Exercised		(246	)				4,221
Expired		(39	)				845,250

Outstanding at December 31, 2017		14,049		$	1,225-19,712,000	$	1,569		4.88

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Fair Value Measurements (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Schedule of fair value of the warrants

The fair value of the Warrants at March 31, 2018 and December 31, 2017 was determined by using option pricing models with the following assumptions:


	March 31, 2018	December 31, 2017
Expected life (in years)	0.58 - 5.87	0.82 - 4.88
Expected volatility	122.68% - 291.61%	130.88% - 266.92%
Risk-free interest rates	1.95% - 2.63%	1.68% - 2.06%

The fair value of the Warrants at December 31, 2017 was determined by using option pricing models assuming the following:


	November 2017 Warrants			October 2016 Warrants			July 2015 Series A Warrants			February 2015 Warrants			October 2013 Warrants
Expected volatility		217.39	%		130.88	%		161.87	%		169.95	%		266.92	%
Risk free interest rates		1.98	%		2.06	%		1.94	%		1.90	%		1.68	%
Expected life (in years)		4.88			3.76			2.56			2.13			0.82

Assets and liabilities measured at fair value on a recurring basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
(in thousands)	Level 1		Level 2		Level 3		Balance at March 31, 2018
Liabilities
Derivative instrument liabilities	$	—	$	—	$	4,169	$	4,169

Assets and Liabilities Measured at Fair Value on a Recurring Basis


	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	Level 1				Level 2				Level 3				Balance at December 31,
(in thousands)	2017		2016		2017		2016		2017		2016		2017		2016
Liabilities
Derivative instrument liabilities	$	—	$	—	$	—	$	—	$	560	$	18,751	$	560	$	18,751

Fair value measurements using significant unobservable inputs

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at December 31, 2017	$	560
Fair value of warrants issued		18,306
Fair value of warrants exercised		—
Total change in the liability included in earnings		(14,697	)

Balance at March 31, 2018	$	4,169

Fair Value Measurements Using Significant Unobservable

Inputs (Level 3)


(in thousands)	Warrant Liability
Balance at January 1, 2015	$	225
Total change in the liability included in earnings		(564	)
Fair value of warrants issued		4,247
Fair value of warrants exercised		(123	)

Balance at December 31, 2015		3,785
Total change in the liability included in earnings		(12,780	)
Fair value of warrants issued		28,472
Fair value of warrants exercised		(726	)

Balance at December 31, 2016	$	18,751
Total change in the liability included in earnings		(15,103	)
Extinguishment of convertible note warrant		(17,489	)
Fair value of warrants issued		16,953
Fair value of warrants exercised		(2,552	)

Balance at December 31, 2017	$	560

Commitments (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments, net of receipts due under terms of subleases under all operating leases

Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2017 are as follows:


(in thousands)	Future Lease Payment
2018		872
2019		501
2020		456
2021		281
2022		—
2023		—

	$	2,110

Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Income (Loss) Before Income Taxes

There is no income tax provision for the years ended December 31, 2017, 2016 and 2015.

Income (loss) before income taxes consists of:


	Year Ended December 31,
(in thousands)	2017			2016			2015
Domestic	$	(41,313	)	$	(13,930	)	$	(11,276	)
Foreign		(3,804	)		(4,040	)		(3,428	)

Income (loss) before taxes	$	(45,117	)	$	(17,970	)	$	(14,704	)

Income tax reconciliation

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:


	Year Ended December 31,
(in thousands)	2017			2016			2015
Income taxes using U.S federal statutory rate	$	(15,340	)	$	(6,110	)	$	(4,999	)
Tax Cuts and Jobs Act		143			—			—
Nondeductible interest		6,912			—			—
Loss on extinguishment of debt		10,174
Loss of tax benefit of federal net operating loss carryforwards		5,067			68,795			—
Loss of tax benefit of state net operating loss carryforwards		1,373			13,891			—
Loss of tax benefit of federal tax credit carryforwards		324			4,023			—
Amortization of gain on IP migration		767			767			767
State income taxes, net of federal benefit		(1,339	)		(2,576	)		380
Foreign rate differential		1,196			1,141			920
Valuation allowance		(1,423	)		(75,407	)		2,649
Derivative charge		(8,403	)		(4,345	)		(192	)
Stock option exercises and cancellations		841			53			674
Research and development costs		(295	)		(250	)		(199	)
Other		3			18			—

	$	—		$	—		$	—

Significant components of deferred tax assets

Significant components of the Company’s deferred tax assets are as follows:


	Year Ended December 31,
(in thousands)	2017		2016		2015
Deferred tax assets:
Employee compensation accruals	$	292	$	1,386	$	1,279
Accrued liabilities		353		343		633
Research tax credits		17		22		3,796
Other		34		55		66
Net operating losses		5,289		6,194		77,906

Total deferred tax assets		5,985		8,000		83,680

Deferred tax liabilities:
Beneficial conversion feature		—		906		—
Other		13		—		—
Total deferred tax liabilities		13		906		—

Valuation allowance		5,972		7,094		83,680

Net deferred tax assets	$	—	$	—	$	—

Summary of Change in Valuation Allowance

The primary reason for the significant decrease in the valuation allowance during 2016 is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows:


(in thousands)	December 31, 2017			December 31, 2016
Beginning balance	$	7,094		$	83,680
Charged to costs and expenses		(1,423	)		(75,407	)
Charged to additional paid-in capital		—			(1,854	)
Charged to retained earnings		—			1,010
Charged to other comprehensive income		301			(335	)

Ending balance	$	5,972		$	7,094

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Selected quarterly financial data

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2017 and 2016.


	2017 Quarters Ended
(in thousands, except per share amounts)	March 31			June 30			September 30			December 31
Revenue	$	743		$	584		$	684		$	704
Costs and expenses		4,736			5,050			5,139			5,254
Operating loss		(4,212	)		(4,601	)		(4,627	)		(4,725	)
Net loss		(11,332	)		(1,943	)		(12,596	)		(19,246	)
Basic loss per share		43,750			1,750			4,680			375

	2016 Quarters Ended
(in thousands, except per share amounts)	March 31			June 30			September 30			December 31
Revenue	$	370		$	511		$	435		$	676
Costs and expenses		3,721			4,232			5,047			4,882
Operating loss		(3,462	)		(3,871	)		(4,724	)		(4,383	)
Net loss		(1,813	)		(6,667	)		(1,004	)		(8,486	)
Basic loss per share		218,750			771,750			115,495			646,010

General - Additional Information (Detail) $ / shares in Units, $ in Thousands				3 Months Ended									12 Months Ended
	May 02, 2018 $ / shares shares	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Mar. 31, 2018 USD ($) Contract $ / shares	Dec. 31, 2017 USD ($) $ / shares	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($)
Class Of Stock [Line Items]
Net loss \| $				$ (7,187)	$ 19,246	$ 12,596	$ 1,943	$ 11,332	$ 8,486	$ 1,004	$ 6,667	$ 1,813	$ 45,117	$ 17,971	$ 14,704
Net cash used in operating activities \| $													15,398
Accumulated deficit \| $				$ 317,645	$ 324,832				$ 279,188				$ 324,832	$ 279,188
Reverse stock split		1:350
Reverse stock split ratio		0.0029	0.0625
Number of fractional shares were issued in connected with the reverse stock split \| shares			0
Common stock, par value (in dollars per share) \| $ / shares			$ 0.01	$ 0.01	$ 0.01				$ 0.01				$ 0.01	$ 0.01
Number of distribution contracts with Turkish distributor \| Contract				1
Subsequent Event [Member]
Class Of Stock [Line Items]
Reverse stock split	1:500
Reverse stock split ratio	0.002
OTCQB [Member]
Class Of Stock [Line Items]
Reverse stock split ratio		0.0029
Number of fractional shares were issued in connected with the reverse stock split \| shares		0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01
OTCQB [Member] \| Subsequent Event [Member]
Class Of Stock [Line Items]
Reverse stock split	1:500
Reverse stock split ratio	0.0020
Number of fractional shares were issued in connected with the reverse stock split \| shares	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017 Segment
Summary Of Significant Accounting Policies [Line Items]
Maximum period of investments with original maturities from date of acquisition to be cash equivalents	3 months
Number of business segments	1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	7 years

Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Earnings Per Share Reconciliation [Abstract]

Net loss

$ 7,187

$ (19,246)

$ (12,596)

$ (1,943)

$ (11,332)

$ (8,486)

$ (1,004)

$ (6,667)

$ (1,813)

$ (45,117)

$ (17,971)

$ (14,704)

Preferred stock dividends

(527)

Net loss, adjusted

$ (45,644)

$ (17,971)

$ (14,704)

Net loss per share - basic and diluted

^[1]

$ (3,250)

$ (1,853,500)

$ (2,548,000)

Weighted average shares outstanding - basic and diluted

^[1]

14,039

[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016, a one-for-three hundred and fifty (1:350) reverse stock split effected on November 6, 2017 and a one-for-five hundred (1:500) reverse stock split effected on May 2, 2018.

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,014,041	41	14,049	41	63
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,014,041	41	14,049	41	65

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 275	$ 298	$ 346
Work-in-process	682	721	214
Finished goods	323	229	100
Total inventories	$ 1,280	$ 1,248	$ 660

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 337	$ 421	$ 501
Financing costs		70
VAT/GST receivable	34	29
Security deposit	49	50	50
Other	134	130
Other		159	147
Total prepaid expenses and other current assets	$ 554	$ 700	$ 698

Prepaid Expenses and Other Current Assets - Additional Information (Detail)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%	5.00%

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 5,191	$ 5,174	$ 4,886
Accumulated depreciation	(4,003)	(3,876)	(3,803)
Property, plant and equipment, net	1,188	1,298	1,083
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	579	579	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,746	1,744	1,532
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,719	1,705	1,504
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	971	971	940
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 176	$ 175	$ 354

Property, Plant, and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 120	$ 74	$ 310	$ 305	$ 617

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Clinical trial expenses	$ 1,603	$ 869	$ 1,365
Compensation, excluding taxes	738	1,124	933
Professional fees	95	221	286
Short-term portion of lease restructuring	197	209	216
Other	893	985	607
Total accrued expenses	$ 3,526	$ 3,408	$ 3,407

Accrued Expenses - Schedule of Accrued Expenses (Parenthetical) (Detail)	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%	5.00%

Restructuring Expenses - Additional Information (Detail) $ in Thousands			3 Months Ended	12 Months Ended
	Aug. 18, 2014 USD ($)	May 22, 2014 USD ($)	Mar. 31, 2018 USD ($) Lease	Dec. 31, 2017 USD ($) Lease	Dec. 31, 2016 USD ($)
Lease Liability [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases \| Lease			2	2
Restructuring reserve charges			$ 0	$ 0
Restructuring reserve balance			546	604	$ 820
Sub-lease 1 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] \| Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] \| Lease Liability [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			300	400
Accrued Expenses [Member] \| Lease Liability [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 200	$ 200

Restructuring Expenses - Schedule of Restructuring and Related Costs (Detail) - Lease Liability [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 604	$ 820
Charges	0	0
Payments/Utilizations	(58)	(216)
Restructuring reserve balance	$ 546	$ 604

Convertible Notes Payable - Additional Information (Detail)																								1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 28, 2017 USD ($)	Nov. 15, 2017 USD ($) $ / shares shares	Nov. 06, 2017	Oct. 11, 2017 USD ($) d $ / shares shares	Oct. 10, 2017 USD ($) Investor shares	Sep. 21, 2017 USD ($) $ / shares	Sep. 15, 2017 USD ($) $ / shares shares	Aug. 28, 2017 USD ($) $ / shares shares	Aug. 04, 2017 USD ($) $ / shares	Jul. 07, 2017 USD ($) $ / shares	Jul. 02, 2017 USD ($) $ / shares	May 09, 2017 USD ($) $ / shares	Apr. 10, 2017 USD ($) $ / shares	Apr. 02, 2017 USD ($)	Mar. 13, 2017 USD ($) $ / shares	Mar. 02, 2017 USD ($) $ / shares	Feb. 10, 2017 USD ($) $ / shares	Feb. 01, 2017 USD ($) $ / shares	Jan. 12, 2017 USD ($) $ / shares	Jul. 21, 2016	Jul. 19, 2016	Jun. 13, 2016	Jun. 06, 2016 USD ($) Installment $ / shares shares	Dec. 31, 2016 USD ($) $ / shares	Jun. 30, 2016 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 28, 2017 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2014 $ / shares
Debt Instrument [Line Items]
Gain (loss) on warrant extinguishment		$ (21,000,000)																										$ 9,613,000		$ 0	$ 0
Warrant liability fair value adjustment																										$ (14,697,000)	$ (1,238,000)	(15,103,000)		(12,780,000)	(564,000)
Debt instrument, conversion price \| $ / shares									$ 5,250.00	$ 12,250.00		$ 8,750.00	$ 10,500.00		$ 19,250.00	$ 24,500.00	$ 35,000.00	$ 56,000.00	$ 63,000.00
Reverse stock split ratio			0.0029																	0.0625
Conversion of convertible notes									$ 1,015,848	$ 2,000,000		$ 1,913,915	$ 3,621,286		$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318							0	$ 12,210,000	40,121,000	$ 35,000,000	649,000	$ 0
Debt instrument extended prepayment date		Mar. 31, 2018
Derivative liability, at calculated fair value																										$ 4,200,000
Fair value of beneficial conversion feature of convertible note																												$ 4,908,000		$ 4,435,000
Minimum [Member]
Debt Instrument [Line Items]
Reverse stock split ratio																					0.1
Exercise price of warrants \| $ / shares																								$ 281,750				$ 1,225		$ 281,750	$ 2,072,000	$ 4,900,000
Maximum [Member]
Debt Instrument [Line Items]
Reverse stock split ratio																					0.05
Exercise price of warrants \| $ / shares																								$ 19,712,000				$ 19,712,000		$ 19,712,000	$ 19,712,000	$ 19,712,000
Additional Paid-in Capital [Member]
Debt Instrument [Line Items]
Fair value of beneficial conversion feature of convertible note																												$ 4,908,000		$ 4,435,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share \| $ / shares											$ 0.001
Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share \| $ / shares						$ 1,000.00
Payment for redemption of preferred stock																												$ 590,000		0	$ 0
Conversion of convertible notes						$ 500,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Gain (loss) on warrant extinguishment					$ (2,300,000)
Initial release of restricted cash								$ 1,650,000
Conversion of convertible notes								$ 1,200,000
Restructuring Agreement [Member] \| Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Preferred stock redemption price per share \| $ / shares								$ 4.20
Restructuring Agreement [Member] \| Series B Preferred Stock [Member]
Debt Instrument [Line Items]
Payment for redemption of preferred stock								$ 2,006,000
Restructuring Agreement [Member] \| Investor [Member] \| Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares								4,200
Restructuring Agreement [Member] \| Investor [Member] \| Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of preferred stock \| shares								2,006
Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								$ 11,444,637
Additional Restructuring [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised \| shares							2,125
Reverse stock split ratio							20
Gain (loss) on warrant extinguishment							$ 1,900,000
Loss on debt settlement							$ 1,200,000
Additional Restructuring [Member] \| New Warrants [Member]
Debt Instrument [Line Items]
Warrants expiry period							42 months
Exercise price of warrants \| $ / shares							$ 61,250
Amendment to Restructuring Agreement [Member]
Debt Instrument [Line Items]
Shares issuable upon warrants exercised \| shares																												735
Exercise price of warrants \| $ / shares																												$ 61,250
Loss on debt settlement				$ 300,000
Warrants issued to purchase Common Stock \| shares				127,551	225																							255
Extinguishment of remaining outstanding obligations under notes	$ 300,000			$ 2,300,000
Loss on debt settlements by issuing warrants				300,000
Term period for warrants																												4 years 6 months
Amendment to Restructuring Agreement [Member] \| Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Redemption of shares outstanding for cash payment				$ 590,000
Exchange Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes		$ 10,562,425
Exercise price of warrants \| $ / shares		$ 1,225
Number of Notes investors entered into agreement	2	2																											2
Warrants issued to purchase Common Stock \| shares		14,000
Extinguishment of remaining outstanding obligations under notes	$ 3,000,000
Term period for warrants		5 years
Debt instrument date of agreement	Dec. 28, 2017	Nov. 15, 2017
Release of restrictions on restricted cash held in control accounts	$ 2,046,898
Cash payment to investors from restricted cash held	829,831
Loss on debt settlements by issuing shares and debt	$ 3,700,000
Exchange Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Percentage of beneficial ownership by investor of issued and outstanding stock	4.90%
Exchange Agreement [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Percentage of beneficial ownership by investor of issued and outstanding stock	9.90%
Securities Purchase Agreement [Member] \| Warrant Repurchase Agreements [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants														$ 7,900,000											$ 7,900,000
Gain (loss) on warrant extinguishment														9,600,000
Warrant liability fair value adjustment														$ 17,500,000
Series C Warrants [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants																												$ 7,876,000		0	0
Release of restrictions on restricted cash held in control accounts																												$ 7,876,000		$ 0	$ 0
Series C Warrants [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share \| $ / shares																							$ 0.01
Series C Warrants [Member] \| Securities Purchase Agreement [Member] \| Warrant Repurchase Agreements [Member]
Debt Instrument [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants																									7,900,000
Senior Secured Convertible Notes [Member] \| Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion of convertible notes											$ 4,200,000
Senior Secured Convertible Notes [Member] \| Amendment to Restructuring Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares				$ 0.05
Number of Notes investors entered into agreement \| Investor					2
Conversion of convertible notes					$ 279,015
Conversion price of debt instrument to purchase price of common stock percentage.				200.00%
Debt instrument, maturity description																												The maturity date (as defined in the notes) shall automatically be extended to the earlier to occur of (x) the first anniversary of the date of consummation of the offering contemplated by the registration statement and (y) December 30, 2018
Debt instrument maturity date				Dec. 30, 2018
Debt instrument, deferred description																												until the earlier of (x) this maturity date and (y) the 75th calendar day after the date of consummation of the offering contemplated by the registration statement, all installments to be made under the notes shall be deemed automatically deferred with no conversions during that 75 day period
Debt instrument, conversion treshhold days \| d				75
Debt instrument, redemption description																												The Company agreed to redeem any portion of the outstanding notes at any time requested by either investor thereto with $7.3 million in cash to be reduced by $0.6 million to redeem the Series C Preferred Stock remaining in the restricted accounts with respect to the 2016 convertible notes
Redemption of outstanding debt instrument for cash				$ 7,300,000
Senior Secured Convertible Notes [Member] \| Amendment to Restructuring Agreement [Member] \| Series C Preferred Shares [Member]
Debt Instrument [Line Items]
Cash held in the restricted accounts				$ 600,000
Senior Secured Convertible Notes [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount		$ 10,600,000
Gain (loss) on warrant extinguishment		(19,000,000)
Aggregate principal amount of notes		11,157,970
Fair value of new notes including conversion feature		15,200,000
Debt instrument, fair value		10,300,000
Senior Secured Convertible Notes [Member] \| Exchange Agreement [Member] \| Additional Paid-in Capital [Member]
Debt Instrument [Line Items]
Fair value of beneficial conversion feature of convertible note	$ 4,900,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																							$ 35,000,000
Debt discount on senior notes																							$ 2,800,000					$ 35,000,000
Proceeds from issuance of notes available for general corporate purposes																								$ 3,000,000
Amortization payments number of equal installments \| Installment																							14
Period after original date of issuance of notes for which amortization payment begins																						7 months
Debt instrument, original issuance date																						Jun. 13, 2016
Debt instrument, conversion price \| $ / shares																							$ 8,537,775
Beneficial conversion feature																												4,400,000
Debt discount amortization																												35,000,000
Debt issuance costs																												$ 2,200,000
Senior Secured Convertible Notes [Member] \| Series C Warrants [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount																									$ 35,000,000
Senior Secured Convertible Notes [Member] \| Series C Warrants [Member] \| Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants																							$ 32,200,000
Debt discount on senior notes																							$ 27,800,000
Shares issuable upon warrants exercised \| shares																							40
Senior Secured Convertible Notes [Member] \| Warrants [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Derivative liability, at calculated fair value		$ 14,400,000
Restricted Notes [Member] \| Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								10,092,857
Unrestricted Notes [Member] \| Restructuring Agreement [Member] \| Investor [Member] \| Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount of notes								1,351,780
Cancellation Note [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal of notes cancelled								$ 1,200,000
Redemption Notes [Member] \| Additional Restructuring [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount							$ 4,000,000
Debt instrument, redemption price							6,436,852.80
Exchange Notes [Member] \| Additional Restructuring [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount							$ 2,436,852.80
Exchange Notes [Member] \| Additional Restructuring [Member] \| New Warrants [Member]
Debt Instrument [Line Items]
Common stock shares purchased \| shares							114,286
New Notes [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price \| $ / shares		$ 750.00
Extinguishment of remaining outstanding obligations under notes	$ 3,027,408
Debt instrument conversion price of lowest vwap for common stock percentage		82.00%
Debt instrument conversion price of lowest vwap for common stock in event of default percentage		75.00%

Convertible Notes Payable - Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes (Detail) - USD ($)																3 Months Ended		12 Months Ended
	Dec. 28, 2017	Nov. 15, 2017	Nov. 06, 2017	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	Jun. 07, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Applicable Conversion Price					$ 5,250.00	$ 12,250.00			$ 8,750.00	$ 10,500.00	$ 19,250.00	$ 24,500.00	$ 35,000.00	$ 56,000.00	$ 63,000.00
Reduction in Principal					$ 1,015,848	$ 2,000,000			$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318	$ 0	$ 12,210,000	$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	247,417
Applicable Conversion Price	$ 10.00	$ 41.72					$ 12,250.00	$ 12,250.00											$ 10.00
Reduction in Principal	$ 2,474,174	$ 8,130,564					$ 4,200,000	$ 4,200,000
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Applicable Conversion Price				$ 5,250.00
Reduction in Principal				$ 1,200,000
Warrant Exchange [Member]
Debt Instrument [Line Items]
Reduction in Principal			$ 279,016
Retirement Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 553,234
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of Shares					83	229			218	344	229	5	87	10	23				642,885
Common Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares	445,152	194,896					1,380	1,380
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of Shares				229
Preferred Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of Shares							4,200	4,200

Convertible Notes Payable - Summary of Common Stock and Preferred Stock Shares Issued under Notes and New Notes (Parenthetical) (Detail) - USD ($)																3 Months Ended		12 Months Ended
	Dec. 28, 2017	Nov. 15, 2017	Oct. 10, 2017	Aug. 28, 2017	Aug. 04, 2017	Jul. 07, 2017	Jul. 02, 2017	Jun. 07, 2017	May 09, 2017	Apr. 10, 2017	Mar. 13, 2017	Mar. 02, 2017	Feb. 10, 2017	Feb. 01, 2017	Jan. 12, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 28, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Reduction in Principal					$ 1,015,848	$ 2,000,000			$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318	$ 0	$ 12,210,000	$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Gain (loss) on warrant extinguishment		$ (21,000,000)																$ 9,613,000		$ 0	$ 0
Restructuring Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal				$ 1,200,000
Gain (loss) on warrant extinguishment			$ (2,300,000)
Loss on debt settlement				$ 1,900,000
Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued	247,417
Reduction in Principal	$ 2,474,174	$ 8,130,564					$ 4,200,000	$ 4,200,000
Gain (loss) on warrant extinguishment	(3,700,000)
Loss on debt settlement							$ 1,000,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Number of shares issued							4,200
Retirement Per Exchange Agreement [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Reduction in Principal	$ 600,000
Common Stock Issued [Member]
Debt Instrument [Line Items]
Number of shares issued					83	229			218	344	229	5	87	10	23				642,885
Common Stock Issued [Member] \| Restructuring Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued				229
Common Stock Issued [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued	445,152	194,896					1,380	1,380
Provision to Exchange [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued		1,948
Reduction in Principal		$ 600,000
Updated Conversion Price Formula [Member] \| Exchange Agreement [Member]
Debt Instrument [Line Items]
Number of shares issued		192,948
Reduction in Principal		$ 7,500,000

Stockholders' Equity - Reverse Stock Split - Additional Information (Detail)	May 02, 2018 $ / shares shares	Nov. 06, 2017 $ / shares shares	Jul. 21, 2016 $ / shares shares	Jul. 19, 2016 shares	Mar. 31, 2018 $ / shares shares	Dec. 31, 2017 $ / shares shares	Dec. 31, 2016 $ / shares shares
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.0029	0.0625
Number of fractional shares were issued in connected with the reverse stock split			0
Common stock, par value (in dollars per share) \| $ / shares			$ 0.01		$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)				170,000,000	500,000,000	500,000,000	500,000,000
Reverse stock split		1:350
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio				0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio				0.05
OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.0029
Number of fractional shares were issued in connected with the reverse stock split		0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01
Subsequent Event [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.002
Reverse stock split	1:500
Subsequent Event [Member] \| OTCQB [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0020
Number of fractional shares were issued in connected with the reverse stock split	0
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Reverse stock split	1:500

Stockholders' Equity - Preferred Stock Issuances - Additional Information (Detail)														1 Months Ended			3 Months Ended		6 Months Ended	12 Months Ended
	Sep. 21, 2017 USD ($) Investor Vote $ / shares shares	Aug. 28, 2017 USD ($) shares	Aug. 04, 2017 USD ($)	Jul. 11, 2017 USD ($) Vote $ / shares	Jul. 07, 2017 USD ($)	Jul. 02, 2017 USD ($) Vote $ / shares shares	May 09, 2017 USD ($)	Apr. 10, 2017 USD ($)	Mar. 13, 2017 USD ($)	Mar. 02, 2017 USD ($)	Feb. 10, 2017 USD ($)	Feb. 01, 2017 USD ($)	Jan. 12, 2017 USD ($)	Oct. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Oct. 31, 2013 USD ($)	Mar. 31, 2018 USD ($) $ / shares	Mar. 31, 2017 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2017 USD ($) $ / shares	Dec. 28, 2017 USD ($)	Dec. 31, 2016 USD ($) $ / shares	Dec. 31, 2015 USD ($)	Nov. 06, 2017 USD ($)	Sep. 12, 2017 $ / shares	Jun. 29, 2017 $ / shares
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																	$ 0.01		$ 0.01	$ 0.01		$ 0.01
Conversion of convertible notes			$ 1,015,848		$ 2,000,000		$ 1,913,915	$ 3,621,286	$ 4,417,829	$ 125,999	$ 3,045,817	$ 544,000	$ 1,478,318				$ 0	$ 12,210,000		$ 40,121,000	$ 35,000,000	$ 649,000	$ 0
Sale of stock in private placement																	$ 4,252,000					1,011,000	8,479,000
Gross proceeds from the sale of shares														$ 1,200,000	$ 2,600,000	$ 7,500,000
Deemed dividend amount																				$ 527,000		$ 0	$ 0
Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes		$ 1,200,000
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																										$ 0.01
Number of Shares \| shares						4,200
Closing bid price \| $ / shares						$ 644,000
Number of votes \| Vote						4,200,000
Preferred stock redemption price per share \| $ / shares						$ 0.001
Series A Preferred Stock [Member] \| Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Conversion of convertible notes						$ 4,200,000
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																										$ 0.01
Closing bid price \| $ / shares				$ 32,787
Number of votes \| Vote				61
Sale of stock in private placement				$ 2,360,000
Cash purchase price in private placement				2,000,000
Gross proceeds from the sale of shares				$ 2,000,000
Conversion price per share \| $ / shares				$ 26,775
Deemed dividend amount																			$ 360,000
Series B Preferred Stock [Member] \| Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Redeemed share \| shares		2,360,000
Series C Preferred Shares [Member]
Stockholders Equity Note [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares																									$ 0.01
Number of Shares \| shares	590
Number of votes \| Vote	2,968
Preferred stock redemption price per share \| $ / shares	$ 1,000.00
Conversion of convertible notes	$ 500,000
Number of investors \| Investor	2
Redemption of preferred stock																								$ 590,000

Stockholders' Equity - Stock and Warrant Issuances - Additional Information (Detail)				1 Months Ended							3 Months Ended	12 Months Ended
	Oct. 11, 2017 shares	Oct. 10, 2017 shares	Apr. 02, 2017 USD ($)	Feb. 28, 2018 USD ($) $ / shares shares	Nov. 30, 2016 USD ($) Investor shares	Oct. 31, 2016 USD ($) shares	Jun. 30, 2016 USD ($) shares	Jul. 31, 2015 USD ($) shares	Feb. 28, 2015 USD ($) shares	Oct. 31, 2013 USD ($) shares	Mar. 31, 2018 $ / shares shares	Dec. 31, 2017 USD ($) Investor $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Nov. 30, 2017 USD ($)	Jun. 06, 2016 USD ($) shares	Oct. 20, 2015 USD ($)	Dec. 31, 2014 $ / shares shares
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)				424,000		2		3,000,000	1	1
Proceeds from issuance of private placement \| $						$ 1,200,000			$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement \| $				$ 4,300,000		$ 1,100,000			$ 2,500,000	$ 6,900,000
Number of warrants outstanding (in shares)												14,049	78	44				9
Sale of units to underwriter								3,000,000
Proceeds of common stock issued, net of related expenses \| $								$ 6,000,000
Number of pre-funded warrants				76,000
Maximum [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 19,712,000	$ 19,712,000	$ 19,712,000				$ 19,712,000
Maximum offering and selling of stock and securities that entity make to raise capital \| $																	$ 71,800,000
Valuation using contractual term											5 years 10 months 13 days	4 years 10 months 17 days
Valuation using volatility rate											291.61%	266.92%
Valuation using risk free rate											2.63%	2.06%
Amendment to Restructuring Agreement [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock	127,551	225										255
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 61,250
Number of warrants outstanding (in shares)												10
Term period for warrants												4 years 6 months
Warrants exercised (in shares)												3
Number of investors \| Investor												2
Shares issuable upon warrants exercised												735
Warrants exercise price description												The warrants contain a cashless exercise provision that allows the holders to exercise each warrant for three shares of common stock.
Securities Purchase Agreement [Member] \| Warrant Repurchase Agreements [Member]
Stockholders Equity Note [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants \| $			$ 7,900,000				$ 7,900,000
Common Stock Issued [Member]
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)											668,855		2	4
Common shares and rights issued												227,287	10
Common Stock Issued [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Common shares and rights issued												224,000
Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Debt instrument, principal face amount \| $																$ 35,000,000
Senior Secured Convertible Notes [Member] \| Common Stock Issued [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Common shares and rights issued												217,800
Series A Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 24,500
Number of warrants outstanding (in shares)												9,000,000
Number of warrants converted								8,000,000
Gross proceeds from underwriting offering \| $								$ 7,000,000
Warrants exercised (in shares)												1,000,000
Net proceeds from exercise of warrants \| $												$ 400,000
Series A And B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued \| $								$ 3,400,000
Series B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercised (in shares)													1,000,000
Net proceeds from exercise of warrants \| $													$ 800,000
Remaining outstanding warrants expired													3,000,000
Warrants expiration date												Jan. 29, 2016
2013 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock										9
Value of warrants issued \| $										$ 1,900,000
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 19,712,000
Number of warrants outstanding (in shares)												9
Term period for warrants												5 years
February 2015 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock									9
Value of warrants issued \| $									$ 800,000
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 24,500
Number of warrants outstanding (in shares)												9
Term period for warrants												5 years
Series C Warrants [Member]
Stockholders Equity Note [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants \| $												$ 7,876,000	$ 0	$ 0
Series C Warrants [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued \| $							27,800,000
Series C Warrants [Member] \| Securities Purchase Agreement [Member] \| Warrant Repurchase Agreements [Member]
Stockholders Equity Note [Line Items]
Aggregate amount to be paid in exchange for cancellation of warrants \| $							7,900,000
Series C Warrants [Member] \| Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Debt instrument, principal face amount \| $							$ 35,000,000
Series C Warrants [Member] \| Senior Secured Convertible Notes [Member] \| Securities Purchase Agreement [Member]
Stockholders Equity Note [Line Items]
Number of warrants converted							40
Shares issuable upon warrants exercised																40
October 2016 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock						1
Value of warrants issued \| $						$ 300,000
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 24,500
Number of warrants outstanding (in shares)												1
Term period for warrants												5 years
Net proceeds from exercise of warrants \| $												$ 100,000
November 2017 Warrants [Member] \| Exchange Agreement [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock					14,049
Value of warrants issued \| $					$ 14,400,000										$ 14,400,000
Warrants exercisable per share price (in dollars per share) \| $ / shares												$ 1,225
Number of warrants outstanding (in shares)												14,049
Term period for warrants												5 years
Number of investors \| Investor					2
February 2018 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued to purchase Common Stock				1,000,000
Value of warrants issued \| $				$ 18,300,000
Warrants exercisable per share price (in dollars per share) \| $ / shares											$ 10.00
Number of warrants outstanding (in shares)											1,000,000
Valuation using exercise price \| $ / shares				$ 10.00
Valuation using contractual term				6 years
Valuation using volatility rate				122.68%
Valuation using risk free rate				1.00%

Stockholders' Equity - Stock Incentive Plans - Additional Information (Detail) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

May 02, 2018

Jul. 31, 2016

Mar. 31, 2018

Mar. 31, 2017

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock option compensation expense

$ 7,000

$ 21,000

$ 50,000

$ 161,000

$ 349,000

Stock options granted

^[1]

Additional compensation expense relating to stock options

$ 6,800

Restricted stock compensation expense

14,000

27,000

79,000

266,000

$ 308,000

Stock Options [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock option compensation expense

7,000

21,000

$ 100,000

$ 200,000

300,000

Stock options granted

Remaining average recognition period for unrecognized compensation expense

5 months 1 day

Aggregate intrinsic value of options outstanding and exercisable

$ 0

Closing stock price (in dollars per share)

$ 450.00

Stock Options [Member] | Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Options granted, term

10 years

Restricted Stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Restricted stock compensation expense

$ 14,000

$ 27,000

$ 100,000

$ 300,000

2004 Stock Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares reserved for the issuance (in shares)

2009 Stock Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares reserved for the issuance (in shares)

Increased number of shares (in shares)

Shares available for grant

Subsequent Event [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares available for grant

Stock options granted

[1]	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Stockholders' Equity - Stock Option Activity (Detail) - $ / shares

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Stock Options, Number of Options [Roll Forward]

Outstanding, beginning of period (in shares)

Granted (in shares)

^[1]

Forfeited (in shares)

Outstanding, end of period (in shares)

Exercisable (in shares)

Stock Options, Exercise Price per Share [Roll Forward]

^[1]

$ 0

Stock Options, Weighted Average Exercise Price [Roll Forward]

^[1]

Outstanding, beginning of period (in dollars per share)

^[1]

$ 0

^[1]

Outstanding, end of period (in dollars per share)

^[1]

^[1]

$ 0

Exercisable (in dollars per share)

^[1]

$ 0

Stock Options, Weighted Average Remaining Life Years [Abstract]

Outstanding

^[1]

0 years

Exercisable

^[1]

0 years

Minimum [Member]

Stock Options, Exercise Price per Share [Roll Forward]

Outstanding, beginning of period (in dollars per share)

^[1]

$ 0

Outstanding, end of period (in dollars per share)

^[1]

^[1]

$ 0

Exercisable (in dollars per share)

^[1]

Maximum [Member]

Stock Options, Exercise Price per Share [Roll Forward]

Outstanding, beginning of period (in dollars per share)

^[1]

Outstanding, end of period (in dollars per share)

^[1]

^[1]

$ 0

Exercisable (in dollars per share)

^[1]

$ 0

[1]	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Stockholders' Equity - Assumptions Used to Determine Estimated Fair Value of Stock Options Granted (Detail) - $ / shares

12 Months Ended

Dec. 31, 2017

Dec. 31, 2015

Assumptions used to determine the fair value of stock options [Abstract]

Weighted average grant date fair value (in dollars per share)

^[1]

$ 0

Stock Options [Member]

Assumptions used to determine the fair value of stock options [Abstract]

Weighted average risk-free interest rates (in hundredths)

2.15%

1.82%

Weighted average expected volatility (in hundredths)

170.42%

97.70%

Weighted average expected option term (in years)

7 years 3 months 14 days

5 years 1 month 24 days

Weighted average grant date fair value (in dollars per share)

$ 82.34

$ 4,964.73

[1]	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Stockholders' Equity - Summary of Non-vested Options (Detail) - $ / shares

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Non-vested Options, Number of Options [Roll Forward]

Non-vested, beginning of period (in shares)

^[1]

Granted (in shares)

^[1]

Vested (in shares)

^[1]

Forfeited (in shares)

^[1]

Non-vested, end of period (in shares)

^[1]

Non-vested Options, Weighted Average Exercise Price [Roll Forward]

Non-vested, beginning of period (in dollars per share)

^[1]

$ 0

Vested (in dollars per share)

^[1]

^[1]

Non-vested, end of period (in dollars per share)

^[1]

^[1]

$ 0

[1]	Due to the May 2, 2018 1-for-500 reverse stock split, and no fractional shares being issued, all numbers are reduced to zero.

Stockholders' Equity - Summary of Restricted Stock Activity (Detail) - Restricted Stock [Member] - $ / shares

12 Months Ended

Dec. 31, 2017

Dec. 31, 2016

Restricted Stock, Number of Shares [Roll Forward]

Outstanding, beginning of period (in shares)

^[1]

Granted (in shares)

^[1]

Vested (in shares)

^[1]

Forfeited (in shares)

^[1]

Outstanding, end of period (in shares)

^[1]

Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]

Non-vested, beginning of period (in dollars per share)

^[1]

$ 0

Vested (in dollars per share)

^[1]

^[1]